Abstract
Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provide new options for the management of ALK-positive NSCLC.
©2014 American Association for Cancer Research.
MeSH terms
-
Anaplastic Lymphoma Kinase
-
Antineoplastic Agents / therapeutic use*
-
Carbazoles / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Crizotinib
-
Drug Resistance, Neoplasm / genetics
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Mutation
-
Piperidines / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles / therapeutic use
-
Pyridines / therapeutic use
-
Pyrimidines / therapeutic use
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Sulfones / therapeutic use
Substances
-
Antineoplastic Agents
-
Carbazoles
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyridines
-
Pyrimidines
-
Sulfones
-
Crizotinib
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
RON protein
-
Receptor Protein-Tyrosine Kinases
-
ceritinib
-
alectinib